Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

A Single-Center, Single-Dose, Double-Blind, Double-Dummy, Placebo-Controlled, Randomized Crossover Study to Evaluate the Abuse Potential of Intranasal Esketamine Compared to Racemic Intravenous Ketamine in Nondependent, Recreational Users of Perception-Altering Drugs

To see complete record on, please visit this link

Id: NCT02682225

Organisation Name: Janssen Research & Development, LLC

Overal Status: Completed

Start Date: March 25, 2016

Last Update: March 16, 2017

Lead Sponsor: Janssen Research & Development, LLC

Brief Summary: The primary objective of this study is to evaluate the abuse potential of intranasal esketamine (112 milligram and 84 mg) compared to racemic intravenous ketamine (0.5 mg/kg) in nondependent, recreational polydrug users of perception-altering drugs.

  • Drug Abuse

Total execution time in seconds: 0.31270503997803